Back |
home / stock / clls / clls message board
Subject | By | Source | When |
---|---|---|---|
Your call is good. Poot | ~Angel~ | investorshub | 05/27/2015 7:45:05 PM |
:) | Pennybuster | investorshub | 05/27/2015 5:32:19 PM |
Hehe PB it doesn't get much easier bro :) | MrPoppaGeorgeo | investorshub | 05/27/2015 5:31:15 PM |
sweet move here! | Pennybuster | investorshub | 05/27/2015 5:26:12 PM |
$CLLS 41.35 weeeeee | MrPoppaGeorgeo | investorshub | 05/27/2015 3:18:41 PM |
$CLLS booom from $34------->$40 now | MrPoppaGeorgeo | investorshub | 05/27/2015 2:44:22 PM |
$CLLS still goin | MrPoppaGeorgeo | investorshub | 05/27/2015 1:27:32 PM |
Clls boom | MrPoppaGeorgeo | investorshub | 05/26/2015 3:38:52 PM |
Clls looking solid | MrPoppaGeorgeo | investorshub | 05/26/2015 2:56:24 PM |
Et say your booty bounce too..lol | MrPoppaGeorgeo | investorshub | 05/23/2015 9:38:14 PM |
Will bounce back to $37 very easy and | ~Angel~ | investorshub | 05/23/2015 8:39:58 PM |
It popped to $37 in 2 seconds yesterday, | MrPoppaGeorgeo | investorshub | 05/23/2015 8:29:11 PM |
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...